GeneralConnection.com ➔ Dictionary
Dictionary Search

remicade

Synonyms

Noun

1. infliximab

2. Remicade, anti-TNF compound

Usage
Demand for Remicade Biosimilar in USA | Global Market Analysis Report - 2035 - Future Market Insights
Comparison ASP of Remicade vs biosimilars in the U.S. Q4 2024 - Statista
How Long Does Remicade Take to Work for Ulcerative Colitis? - HealthCentral
The Biosimilar Shift: Trending Infliximab Biosimilar Utilization and Associated Cost Savings for Commercial Insurance - AJMC
Celltrion expands US market reach as Zymfentra and Inflectra secure major formulary listings - koreabiomed.com
Methotrexate is safer second-line sarcoidosis treatment than MMF - Sarcoidosis News
Zymfentra Launch: Here’s How to Switch to Zymfentra - GoodRx
Q&A: Remicade treatment weakens COVID-19 antibody response in IBD - Healio
UC Remission: Is Combination Therapy the Key? - WebMD
Implications of the First Liquid IV Infliximab Biosimilar - BioPharm International
Remicade and pregnancy, breastfeeding, and more - Medical News Today
FDA Approves First Subcutaneous Infliximab Product - Center for Biosimilars
FDA SIDE EFFECTS UPDATE: Remicade and the Onset of New Autoimmune Diseases, Plus More - MedShadow Foundation
Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch - statnews.com
Inflectra, a Remicade Biosimilar, Now Available Through Medicare and Medicaid - Arthritis Foundation
Biosimilars of infliximab - Generics and Biosimilars Initiative
J&J unfazed by falling Remicade sales - BioPharma Dive
University of North Carolina Study Finds Infliximab Biosimilars Comparable to Remicade in Gastroenterology and Rheumatology Clinics - Managed Healthcare Executive
Corticosteroid Premedication for Infliximab Remains Unnecessarily Common - AJMC
Study: Remicade effective for sarcoidosis of nerves or liver, not muscles, skin - Sarcoidosis News
J&J's Stelara clinches ulcerative colitis nod to back up declining Remicade - Fierce Pharma
FLIXABI®, an Infliximab Biosimilar Candidate Referencing Remicade®, Receives Positive CHMP Opinion - Biogen
Remicade Class Action Suit Settled by J&J - Anton Health
One of the world’s blockbuster drugs might not exist if its research hadn't flopped in a major way - Business Insider
Which Biologic Is Best for Uveitis in Behcet’s Disease? What a New Study Found - CreakyJoints
Treating IBD with Humira, Remicade May Increase Risk of Kidney Damage: Study - AboutLawsuits.com
Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease - NEJM Evidence
In VA Study, Many Patients Who Tried Biosimilar Infliximab Went Back to Remicade - Center for Biosimilars
J&J offered doctors free services and profit-making advice to boost Remicade scripts: whistleblower suit - Fierce Pharma
Zymfentra, a Subcutaneous Formulation of Infliximab, Approved for IBD - Medical Professionals Reference
Mass spectrometry comparison of Remicade and Remsima - Generics and Biosimilars Initiative
Development of Anti-Drug Antibodies to Infliximab (Remicade®) and Adalimumab (Humira®) in Patients With Crohn’s Disease - 2 Minute Medicine
Comparison of WAC of Remicade vs biosimilars in the U.S. as of Q1 2026 - Statista
FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab) - PR Newswire
Crohn's disease medication: What if they stop working? - Medical News Today
TDM does not improve treatment efficacy during Remicade therapy for inflammatory diseases - Healio
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars (rerun) - Drug Channels
How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal - Fierce Pharma
Avsola, a Biosimilar to Remicade, Gets FDA Approval - Medical Professionals Reference
J&J Settles Pfizer's Antitrust Suit Over Remicade Biosimilar - Law360
FDA approves Avsola, fourth Remicade biosimilar - Healio
J&J’s Remicade: Rebates and High Net Prices, Not Low Net Prices, Inform Market Shares for Remicade and Biosimilar Competitors - The Capitol Forum
Pfizer is taking its fight with J&J over a blockbuster drug to court - Business Insider
Pfizer Alleges J&J Thwarted Competition to Remicade, in Legal Test of Biotech-Drug Copies - WSJ
J&J keeping Remicade biosimilars at bay through price drops - BioProcess International
Johnson & Johnson falls short in a Remicade patent case as star drug slips in Q4 - Fierce Pharma
Johnson & Johnson's Stelara, Tremfya step up in Q4 as Remicade's decline speeds - Fierce Pharma
Pfizer Resolves Antitrust Lawsuit With J&J Over Remicade - Center for Biosimilars
Johnson & Johnson Loses Remicade Patent in Appeal Ruling - Bloomberg.com
Merck lowers cost of Remicade in UK as biosimilars enter market - BioPharma Dive
Remicade, Stelara have similar speed of onset in Crohn’s - Healio
FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union - Biogen
Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars - Drug Channels
Remicade copy clears FDA, becomes second biosim to win approval in U.S. - BioPharma Dive
Study: Many Ankylosing Spondylitis Patients Who Stop Taking Infliximab (Remicade) Wind Up Relapsing - CreakyJoints
Should I Switch My Rheumatoid Arthritis Meds? A Patient Weighs the Pros and Cons - CreakyJoints
What Happens When an Anti-TNF Fails for RA - Arthritis Foundation
J&J: Remicade holding up better than expected - BioPharma Dive
J&J braces for biosim attack after losing last-ditch Remicade patent fight - Fierce Pharma
Remicade Biosimilar Market to Reach USD 4.01 Billion By 2035 At a 5.4% CAGR, Driven By Rising Demand For Cost-Effective Autoimmune Treatments | FMI - Yahoo Finance
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval - Reuters
Want to Switch Back to a Biologic IBD Drug After Taking a Biosimilar? New Study Says It's Safe - CreakyJoints
J&J abandons Remicade patent fight against Samsung and its Renflexis biosim - Fierce Pharma
Second biosimilar of Remicade approved in the US, but J&J not rattled - BioPharma Dive
Treating IBD During Pregnancy - Johns Hopkins Medicine
J&J says ready to fend off Remicade competitor - pharmaphorum
Pfizer accuses Johnson & Johnson of 'anticompetitive practices' in lawsuit - USA Today
Celltrion taps Intract Pharma to develop world's first oral Remicade biosimilar - Fierce Pharma
Top stories in gastroenterology: Ibsrela improves symptoms of IBS subtype, Remicade best for biologic-naive ulcerative colitis - Healio
FDA OK’s new Remicade copycat but no launch planned - BioPharma Dive
The Man Who Discovered Remicade Is All for Biosimilars - Business Insider
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report - Fierce Pharma
Pfizer, Johnson & Johnson Settle Antitrust Suit Over Remicade - Bloomberg Law News
Lack of Interchangeable Biosimilars Keeps J&J in the Infliximab Game - BioProcess International
The Medical Minute: Biosimilars for your IBD? Nothing to fear here! - Penn State Health News
Remicade (infliximab) antitrust $25M class action settlement - Class Action Lawsuits
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications - MDEdge
Celltrion Wins FDA Approval for First Subcutaneous Version of IBD Drug Infliximab - BioSpace
With its Remicade biosimilar stymied by the brand, Pfizer sues Johnson & Johnson for 'anticompetitive' dealmaking - Fierce Pharma
When Patients Develop Antibodies to TNF Inhibitors - MedCentral
Merck, Samsung Bioepis Launch Remicade Biosimilar in U.S. - Genetic Engineering and Biotechnology News
Celltrion taps Lonza to produce some of its Remicade biosimilar - BioPharma Dive
Pfizer sues J&J over Remicade contracts - BioPharma Dive
FDA Approves First Subcutaneous Infliximab for IBD - Managed Healthcare Executive
Remicade Lawsuits - AboutLawsuits.com
Is It Time to Embrace an Alternative to Anti-TNF Meds for Treating Inflammatory Bowel Disease? - CreakyJoints
Merck Announces US Launch of Biosimilar Infliximab Renflexis - Center for Biosimilars
Pfizer, Johnson & Johnson settle high-profile Remicade biosim lawsuit on undisclosed terms - Fierce Pharma
What’s It Like Having COVID When You’re Immunocompromised — and What I’m Still Worried About - CreakyJoints
Weight Gain on Infliximab Tied to Sex, Crohn Disease, and Disease Severity - Gastroenterology Advisor
Pfizer Plans to Launch Remicade Biosimilar in November - WSJ
Remicade biosimilars hit European market - PMLiVE
After strong FDA panel backing, Celltrion & Pfizer's Remicade copycat could become 2nd US biosim - BioPharma Dive
Celltrion files infliximab patent lawsuit in US - Generics and Biosimilars Initiative
Biogen launches Remicade biosimilar in the UK - PMLiVE
What's the Best New Drug for Luminal Crohn's Disease? - MedPage Today
Pfizer’s IXIFI® will be available in Canada as of April 1, 2025 - BioSpace
Infliximab-Induced Interstitial Pneumonitis: A Case Report - Cureus
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis - The New England Journal of Medicine
J&J faces FTC probe on Remicade biosimilar defence - pharmaphorum
Foreign Language Equivalents
Foreign Language Equivalents of 'remicade'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
remicadde,   remicde,   remixade,   renicade,   remicaed,   remicafe,   remicsde,   temicade,   remucade,   remciade,   reemicade,   emicade,   rmicade,   reicade,   remicaade,   remiicade,   remicae,   remicadw,   re,icade,   eemicade,   rmeicade,   remicadee,   remicdae,   rrmicade,   remicad,   remcade,   remiade,   rwmicade,   remicadr,   remiacde,   remivade,   remmicade,   remiccade,   ermicade,   rremicade,   reimcade,   remicase,   remocade
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z